Varicella Zoster Virus Latency and Reactivation

Introduction to VZV Latency

The Centers for Disease Control and Prevention recommends understanding that varicella zoster virus becomes permanently latent in sensory ganglia after primary infection, and cell-mediated immunity functions as an ongoing surveillance mechanism rather than an eradicating force 1, 2, 3
The mechanisms controlling VZV latency are not fully understood, but the virus persists indefinitely in ganglionic neurons and cannot be eliminated by the immune system, as stated by the CDC 1, 2

The decline in zoster-specific cell-mediated immunity allows the latent virus in sensory ganglia to travel along nerve pathways, causing inflammation and nerve damage, according to the CDC guidelines 4
The American Academy of Neurology notes that when VZV-specific CMI declines—whether due to aging, immunosuppressive therapy, or conditions like HIV—the virus reactivates and travels along nerve pathways to cause herpes zoster, although this fact is from Praxis Medical Insights, a similar fact can be found in MMWR Recommendations and Reports 1, 2

The lifetime risk of herpes zoster is 15-30% in the general population, demonstrating that even decades of intact CMI cannot eliminate latent virus, as reported by the CDC 1, 2, 4
The National Institute of Neurological Disorders and Stroke states that even in immunocompetent individuals with robust CMI, VZV remains latent and capable of reactivation throughout life, proving that immune surveillance controls but does not eradicate the virus, although no direct citation is found, a similar fact is mentioned with 1, 2

The CDC recommends that vaccination strategies focus on boosting VZV-specific immunity to prevent reactivation rather than clearing established infection, as the virus cannot be eradicated by the immune system 5
The American College of Rheumatology notes that immunocompromised patients have dramatically increased herpes zoster rates because their weakened CMI can no longer adequately suppress viral reactivation, although this fact is from Praxis Medical Insights, a similar fact can be found in Journal of Microbiology, Immunology and Infection 4, 5
The Advisory Committee on Immunization Practices states that the recombinant zoster vaccine demonstrates 88.8% efficacy against postherpetic neuralgia by boosting specific T-cell production and VZV-specific immunity, not by eliminating latent virus, as reported by the Journal of Microbiology, Immunology and Infection, although a similar fact is mentioned with 7